Pharvaris Stock Upgraded as Oral Therapy Shows Promise
Operators in the HAE market should prepare for a potential shift to oral treatments following strong clinical trial results.
Updated on Oct. 26, 2026 in Healthcare
Live Poll
Do you trust bank stock ratings when deciding to add pharmaceutical companies to your portfolio?
Bank of America upgraded Pharvaris stock to Buy, citing strong Phase 3 clinical data for its oral hereditary angioedema (HAE) treatment. The move comes as the company prepares for upcoming regulatory milestones for its prevention and on-demand therapies.
Why it matters
The upgrade reflects a shift in market sentiment regarding deucrictibant, as the drug demonstrates efficacy levels that could significantly challenge existing treatments. For operators in the healthcare sector, the success of an oral alternative to current injectable therapies signals a potential disruption in patient management and long-term market share.
Pharvaris reported an 83% reduction in HAE attack rates during its CHAPTER-3 phase 3 trial, compared to the 44% to 50% reduction seen with BioCryst's Orladeyo. The stock price closed at $31.41 on October 23, 2026, against a new Bank of America price target of $44.
The players
Pharvaris
A clinical-stage biopharmaceutical company focused on developing oral therapies for bradykinin-mediated diseases.
Bank of America
A global financial institution providing research, investment banking, and capital market services to institutional clients.
BioCryst
A pharmaceutical company that develops and markets Orladeyo, an oral therapy currently used to treat hereditary angioedema.
The details
Pharvaris's deucrictibant distinguishes itself in the HAE market by offering an oral delivery method instead of the standard injection-based protocols. The CHAPTER-3 trial results effectively de-risk the clinical profile of the drug, clearing a path for the company to seek FDA approval for its prevention-focused version in the first half of 2027. With projected peak sales of $917 million for the prevention product, the firm is positioning itself to capture significant market share among the estimated 7,500 HAE patients in the United States.
Timeline
October 23, 2026: Bank of America upgraded Pharvaris to Buy.
First half of 2027: Pharvaris plans to file for approval of the prevention version.
April 23, 2027: The FDA decides on the on-demand version of deucrictibant.
Market Landscape
The development of deucrictibant marks a significant shift in the competitive landscape for hereditary angioedema treatment. It directly follows the established market presence of BioCryst's Orladeyo, aiming to displace it through higher reported efficacy rates.
Healthcare operators should monitor the April 2027 FDA decision as a signal for potential changes in standard-of-care reimbursement and prescribing patterns. This shift to more potent oral treatments may require supply chain and pharmacy benefit managers to reevaluate current HAE coverage policies.
The takeaway
The competitive gap between injectable and next-generation oral HAE treatments is narrowing as trial data shows superior efficacy for newer entrants. Industry leaders should track the progress of the upcoming FDA on-demand product filing for insights into how pricing and market access may evolve by 2028.
Further reading
For more on the current shifts in pharmaceutical development and regulation, visit the Healthcare section.
Source note: This article includes information reported by The Fresno Bee.
Live Poll
Do you trust bank stock ratings when deciding to add pharmaceutical companies to your portfolio?
